E-LIB Suche - Ergebnisse für: Jalundhwala, Y.J.

1

Content validity of MANAGE-PD tool: Real-world evidence fro..:

Fernandez, H. ; Odin, P. ; Standaert, D....
Parkinsonism & Related Disorders. 79 (2020) - p. e46-e47 , 2020

Link: https://doi.org/10.1016/..

2

Improvement in Health-related quality of life for Sickle Ce..:

Jalundhwala, Y.J. ; Saraf, S.L. ; Rondelli, D...
Value in Health. 18 (2015) 3 - p. A302 , 2015

Link: https://doi.org/10.1016/..

3

Systematic review of pharmacologic therapies for neuropathi..:

Sudharshan, L. ; Snedecor, S.J. ; Cappelleri, J.C....
Value in Health. 16 (2013) 3 - p. A113 , 2013

Link: https://doi.org/10.1016/..

4

Abdominal Compartment Syndrome: Predictors of Adverse Outco..:

Shaheen, A.W. ; Crandall, M. ; Merlotti, G.J...
Journal of Surgical Research. 179 (2013) 2 - p. 198 , 2013

Link: https://doi.org/10.1016/..

5

Systematic review and meta-analysis of pharmacological ther..:

Snedecor, S. ; Sudharshan, L. ; Cappelleri, J....
The Journal of Pain. 14 (2013) 4 - p. S11 , 2013

Link: https://doi.org/10.1016/..

6

Considerations Of Practical Challenges In Conducting Mixed ..:

Jalundhwala, Y.J. ; Lin, F.J. ; Patel, H.
Value in Health. 16 (2013) 3 - p. A212 , 2013

Link: https://doi.org/10.1016/..

7

DB2 Vitamin D Deficiency and Diabetes: Perceptions of Pharm..:

Jalundhwala, F. ; Majumdar, A. ; Malthankar, S..
Value in Health. 15 (2012) 7 - p. A603-A604 , 2012

Link: https://doi.org/10.1016/..

8

PIH19 IMPACT OF SEVERITY DIFFERENCES ON LOGICAL INCONSISTEN..:

Jalundhwala, Y ; Shaw, JW ; Pickard, AS..
Value in Health. 13 (2010) 3 - p. A184 , 2010

Link: https://doi.org/10.1016/..

9

Characterizing advanced Parkinson's disease: OBSERVE-PD obs..:

Fasano A ; Fung V. S. C ; Lopiano L...
info:eu-repo/semantics/altIdentifier/pmid/30940119. , 2019

Link: http://hdl.handle.net/23..

10

Does the 5–2-1 criteria identify patients with advanced Par..:

Malaty, Irene A. ; Martinez-Martin, Pablo ; Chaudhuri, K. Ray...
BMC Neurology. 22 (2022) 1 - p. , 2022

Link: https://doi.org/10.1186/..

11

Efficacy and safety of glecaprevir/pibrentasvir in renally ..:

Lawitz, Eric ; Flisiak, Robert ; Abunimeh, Manal...
Liver International. 40 (2019) 5 - p. 1032-1041 , 2019

Link: https://doi.org/10.1111/..

12

The Cost Effectiveness of Levodopa-Carbidopa Intestinal Gel..:

Chaudhuri, KR ; Pickard, AS ; Alobaidi, A...
https://discovery.ucl.ac.uk/id/eprint/10146024/3/Sayed_s40273-022-01132-y.pdf. , 2022

Link: https://discovery.ucl.ac..

13

Does the 5–2-1 criteria identify patients with advanced Par..:

Malaty, Irene A ; Martinez-Martin, Pablo ; Chaudhuri, K. Ray...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8785442/. , 2022

Link: http://www.ncbi.nlm.nih...

14

Does the 5–2-1 criteria identify patients with advanced Par..:

Irene A. Malaty ; Pablo Martinez-Martin ; K. Ray Chaudhuri...
https://doi.org/10.1186/s12883-022-02560-1. , 2022

Link: https://doi.org/10.1186/..

15

Additional file 1 of Does the 5–2-1 criteria identify patie..:

Irene A. Malaty (8029040) ; Pablo Martinez-Martin (3179352) ; K. Ray Chaudhuri (8967020)...
https://figshare.com/articles/journal_contribution/Additional_file_1_of_Does_the_5_2-1_criteria_identify_patients_with_advanced_Parkinson_s_disease_Real-world_screening_accuracy_and_burden_of_5_2-1-positive_patients_in_7_countries/19028915. , 2022

Link: https://doi.org/10.6084/..